GSK Statement on First Phase 1 Trial Results of a Candidate Ebola Vaccine

November 24, 2014 First results from a small phase 1 trial published today in the New England Journal of Medicine show that a GSK/NIH Ebola candidate vaccine was well-tolerated and produced an immunological response in each of the 20 healthy adult volunteers in the USA who received it. The candidate vaccine used in the trial conducted by the National Institutes …

Merck enters the Ebola Vaccine Race in NewLink Partnership

Merck obtains the rights to NewLink genetics’ experimental Ebola Vaccine, putting pressure on GSK Merck has struck a agreement with NewLink Genetics to licence their investigational Ebola vaccine, rVSV-EBOV. The $50 million agreement gives Merck exclusive rights to develop, manufacture, and distribute the vaccine across the world. This partnership should allow NewLink to keep pace with the huge effort by …

Safety sweep of the NIH reveals presence of five dangerous toxic samples

NIH Finds Unauthorised Toxic Samples In Safety Sweep

Safety sweep of the NIH reveals presence of five dangerous toxic samples In July 2014, a number of unauthorised smallpox samples were discovered at the NIH’s headquarters in Bethseda, Maryland. This discovery spurred on a safety sweep of the NIH headquarters to verify the presence of any other unauthorised biological samples and toxins. On the 5th of September, it was …

Ebola vaccine trials fast-tracked by international consortium

Unprecedented international consortium assembled to accelerate collaborative multi-site trials of candidate Ebola vaccine August 28, 2014 A candidate Ebola vaccine could be given to healthy volunteers in the UK, The Gambia and Mali as early as September, as part of a series of safety trials of potential vaccines aimed at preventing the disease that has killed more than 1,400 people …

NIH Establishes Monkey Model for MERS-CoV

An NIH study suggests that marmoset models are the optimum option for testing new drugs for MERS Scientists from the National Institutes of Health have found that the Middle East Respiratory (MERS) virus in marmosets provokes a very similar response to humans afflicted with MERS caused pneumonia. The doctors began testing MERS treatments on marmosets after using computer models to …

Chikungunya vaccine candidate causes successful development of antibodies against the virus

Chikungunya Vaccine Candidate Passes Phase I Clinical Trials

Chikungunya vaccine candidate causes successful development of antibodies against the virus Chikungunya, a mosquito borne virus, has recently been responsible for outbreaks in the Caribbean and the Pacific. Although the disease is not usually fatal, it causes similar symptoms to a bad flu: muscle aches, malaise and headaches. However, one of the unique aspects of the virus is that it …

CEL-SCI Receives $225,000 NIH Research Grant to Develop Rheumatoid Arthritis Treatment

Pre-clinical studies show CEL-SCI’s LEAPS technology prevented the development and lessened the severity of rheumatoid arthritis July 15, 2014 CEL-SCI Corporation announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant in the amount of $225,000 from the National Institute of Arthritis Muscoskeletal and Skin Diseases (NIAMS), which is part of the National Institutes of …